{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:27:21Z","timestamp":1793114841230,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ijantimicag.2018.04.001","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T12:44:54Z","timestamp":1523450694000},"page":"287-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Molecular \u03b2-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets"],"prefix":"10.1016","volume":"52","author":[{"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah N.","family":"Woosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-2978","authenticated-orcid":false,"given":"Patricia A.","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0001","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1128\/AAC.01257-13","article-title":"Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection","volume":"57","author":"Singh","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0002","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0003","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0004","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2015.199","article-title":"The emerging threat of multidrug-resistant Gram-negative bacteria in urology","volume":"12","author":"Zowawi","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0005","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1128\/AAC.00540-16","article-title":"Changes in the frequencies of \u03b2-lactamase genes among Enterobacteriaceae isolates in U.S. Hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against \u03b2-lactamase-producing isolates","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0006","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.aambs.2014.09.002","article-title":"Escherichia coli ST131: The quintessential example of an international multiresistant high-risk clone","volume":"90","author":"Mathers","year":"2015","journal-title":"Adv Appl Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0007","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1128\/AAC.01173-15","article-title":"\u03b2-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates","volume":"60","author":"Mendes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0008","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10 x '20 Progress\u2013development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0009","series-title":"Zavicefta\u00ae Package Insert","year":"2016"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0010","series-title":"AVYCAZ\u00ae (ceftazidime-avibactam)","year":"2017"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0011","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0012","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection - results from a randomized, controlled, double-blind, Phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0013","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02447-16","article-title":"Molecular \u03b2-lactamase characterization of aerobic Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections: efficacies analyzed against susceptible and resistant subsets","volume":"61","author":"Mendes","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0015","series-title":"Performance standards for antimicrobial susceptibility testing: 25th informational supplement","year":"2015"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0016","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0017","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fmicb.2012.00110","article-title":"CTX-M enzymes: origin and diffusion","volume":"3","author":"Canton","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0018","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against Class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0019","series-title":"DORIBAX (doripenem) package insert","year":"2009"},{"key":"10.1016\/j.ijantimicag.2018.04.001_bib0020","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1128\/AAC.01282-16","article-title":"Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant \u03b2-lactam resistance mechanisms","volume":"60","author":"Torrens","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918301031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918301031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T10:44:31Z","timestamp":1561718671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918301031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0924857918301031"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.04.001","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular \u03b2-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}